Sarclisa market seen growing on cancer burden and aging population

The Business Research Company says the global Sarclisa market is set to expand through 2035 as multiple myeloma cases rise, oncology treatment options improve and older populations grow. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Sarclisa is tied to treatment for multiple myeloma, a blood cancer with a growing global patient pool. - The market outlook matters because demand is being pushed by broader cancer incidence, an aging population and wider use of biologic therapies. - The report also points to combination immunotherapies and targeted biologics as part of the next phase of oncology care.

What happened: - The Business Research Company released its In-Depth Sarclisa Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Sarclisa market is positioned for steady expansion through the forecast period. - The company identifies North America as the largest regional market in 2025. - The report projects Asia-Pacific will be the fastest-growing region in the years ahead. - A free sample of the Sarclisa market report is available. - The full Sarclisa market report is also available.

The details: - Sarclisa is a monoclonal antibody used to treat certain cancers, especially multiple myeloma. - The drug binds to the CD38 protein on multiple myeloma cells. - That binding helps the immune system identify and destroy cancer cells. - Sarclisa is commonly used with other cancer therapies to improve outcomes. - Historic market growth was driven by rising multiple myeloma cases, monoclonal antibody advances, more oncology centers, better blood cancer diagnostics and higher adoption of biologic therapies. - Future growth is expected to be supported by investment in next-generation oncology drugs, more combination immunotherapies, personalized cancer treatment, targeted biologics and additional regulatory approvals. - Forecast-period trends include wider use of CD38-targeted monoclonal antibodies, more combination treatment protocols, greater emphasis on personalized cancer care, expanded biologics manufacturing and more focus on treatment safety and effectiveness. - Cancer burden is a major driver of demand. - PubMed projected in November 2024 that global cancer cases could reach 35.3 million by 2050, up 76.6% from 20 million in 2022. - PubMed also projected cancer deaths could reach 18.5 million by 2050, up 89.7% from 9.7 million in 2022. - Aging is another growth driver. - The World Health Organization said in October 2024 that one in six people worldwide will be over 60 by 2030. - The WHO said the over-60 population is expected to double by 2050 to 2.1 billion. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, a company scoring matrix, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The report frames Sarclisa’s outlook as part of a broader shift toward precision oncology and biologic treatments. - North America’s lead suggests the market is most mature where access to advanced cancer care is already established. - Faster growth in Asia-Pacific points to room for expansion as treatment access and healthcare investment improve. - The emphasis on safety, effectiveness and combination regimens suggests competition in myeloma care is moving toward better-tolerated and more tailored therapies.

What's next: - The market will likely track cancer incidence, regulatory approvals and adoption of combination myeloma regimens. - Investment in oncology R&D and biologics manufacturing should shape competitive positioning. - Regional growth will depend on how quickly newer therapies reach patients outside North America. - More information is available through The Business Research Company’s report links and contact channels listed in the release.

The bottom line: - Sarclisa’s market case is being strengthened by rising cancer demand, an older global population and continued movement toward targeted biologic treatment.